Sirolimus therapy to halt the progression of ADPKD

Journal of the American Society of Nephrology

Volumn 21, Issue 6, 2010, Pages 1031-1040

  Perico, Norberto ^a   Antiga, Luca ^a   Caroli, Anna ^a   Ruggenenti, Piero ^a,b   Fasolini, Giorgio ^b   Cafaro, Mariateresa ^b   Ondei, Patrizia ^b   Rubis, Nadia ^a   Diadei, Olimpia ^a   Gherardi, Giulia ^a   Prandini, Silvia ^a   Panozo, Andrea ^a   Bravo, Rodolfo Flores ^a   Carminati, Sergio ^a   De Leon, Felipe Rodriguez ^a   Gaspari, Flavio ^a   Cortinovis, Monica ^a   Motterlini, Nicola ^a   Ene Iordache, Bogdan ^a   Remuzzi, Andrea ^a,c   Remuzzi, Giuseppe ^a,b   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF BERGAMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; RAPAMYCIN;

ACNE; ADULT; ALBUMINURIA; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LEUKOPENIA; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VOLUMETRY;

EID: 77952986486     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009121302     Document Type: Article

References (43)

1. Ecter T, Fick-Brosnahan GM, Schrier RW: Polycystic kidney disease. In: Diseases of the Kidney and Urinary Tract, 8th Ed., edited by Schrier RW, Philadelphia, Lippincott Williams & Wilkins, 2007, pp 502-539
2. Harris PC: 2008 Homer W. Smith Award: Insights into the pathogenesis of polycystic kidney disease from gene discovery. J Am Soc Nephrol 20: 1188-1198, 2009
3. Kottgen M: TRPP2 and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1772: 836-850, 2007
4. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP: Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006
5. Gattone VH 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003
6. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004 (Pubitemid 38508512)
7. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997 (Pubitemid 27465366)
8. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004
9. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 124: 471-484, 2006
10. Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell 12: 487-502, 2007
11. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471, 2006
12. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604, 2006
13. Nakamura T, Ebihara I, Nagaoka I, Tomino Y, Nagao S, Takahashi H, Koide H: Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol 3: 1378-1386, 1993
14. Aukema HM, Housini I: Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 59: 52-61, 2001
15. Nishio S, Hatano M, Nagata M, Horie S, Koike T, Tokuhisa T, Mochizuki T: Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J Clin Invest 115: 910-918, 2005
16. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002
17. Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, Serra AL: Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 880-889, 2008
18. Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G: Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 84: 956-964, 2007
19. Douros J, Suffness M: New antitumor substances of natural origin. Cancer Treat Rev 8: 63-87, 1981
20. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356, 2005
21. Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE, SIRIUS Investigators: Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110: 3773-3780, 2004
22. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51, 2005
23. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE: Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 19: 631-638, 2008
24. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP, CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
25. Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, Remuzzi G, Remuzzi A: Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: A progress report. Clin J Am Soc Nephrol 1: 754-760, 2006
26. Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP: Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 24: 3334-3342, 2009
27. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A: Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8: 1384-1392, 2008
28. Gingras AC, Raught B, Sonenberg N: Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001
29. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63: 917-926, 2003
30. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 98: 9666-9670, 2001
31. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259, 2007
32. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323: 1091-1096, 1990 (Pubitemid 20370729)
33. Oroszlan M, Bieri M, Ligeti N, Farkas A, Koestner SC, Meier B, Mohacsi PJ: Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant. J Heart Lung Transplant 27: 1311-1318, 2008
34. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL: Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297: F1597-F1605, 2009
35. Raichlin E, Chandrasekaran K, Kremers WK, Frantz RP, Clavell AL, Pereira NL, Rodeheffer RJ, Daly RC, McGregor CG, Edwards BS, Kushwaha SS: Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation 86: 1395-1400, 2008
36. Chapman AB: Improving clinical trial design for inquiries into the mechanisms of cyst growth in ADPKD. Kidney Int 75: 139-141, 2009
37. Levey AS, Greene T, Kusek J, Beck GJ, MDRD Study Group: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: 155A, 2000
38. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6: 257-263, 1995
39. Cattaneo D, Perico N, Gaspari F: Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 774: 187-194, 2002
40. Otsu N: A threshold selection method from gray-level histogram. IEEE Trans Syst Man Cybern 9: 62-66, 1979
41. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005
42. Ibanez L, Schroeder W, Ng L, Cates J: The ITK Software Guide, 2nd Ed., Albany, Kitware Inc., 2005
43. Senn S: Cross-over Trials in Clinical Research, Chichester, Wiley, 1993